[Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
|
| Abstract |
The objective of study was to evaluate the efficiency and safety of bortezomib for the treatment of multiple myeloma. Bortezomib in combination with dexamethasone was administered as first-line treatment in all 7 newly diagnosed patients with multiple myeloma. The patients with refractory myeloma were treated with bortezomib in combination with dexamethasone or with other traditional agents such as mitoxantrone and thalidomide. The results showed that according to the EMBT criteria, out of 7 patients one achieved complete response (CR), five achived partial response (PR) and one achived minor response (MR). The 3 patients with refractory/relapsed myeloma achieved PR (2/3) and MR (1/3). The overall response rate (CR + PR) was 80%. The most frequent adverse events observed were thrombocytopenia in three patients, diarrhea and peripheral neuropathy in one respectively. In conclusion, bortezomib demonstrates efficiency in the treatment of new-diagnosed and refractory/relapsed multiple myeloma, and the side effects from treatment are acceptable and manageable.
|
|---|---|
| Authors | Li-Xia Wang, Hua Lu, Wen-Yi Shen, Si-Xuan Qian, Hong-Xia Qiu, Han-Xin Wu, Jian-Fu Zhang, Yu-Jie Wu, Jian-Yong Li |
| Journal | Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 16 Issue 4 Pg. 943-5 (Aug 2008) ISSN: 1009-2137 [Print] China |
| PMID | 18718096 (Publication Type: Clinical Trial, English Abstract, Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!